Research outputs
Selected research outputs
- Ultraviolet light-induced collagen degradation inhibits melanoma invasion (Journal article - 2021)
- Female Immunity Protects from Cutaneous Squamous Cell Carcinoma (Journal article - 2021)
- Prognostic gene expression signature for high-grade serous ovarian cancer (Journal article - 2020)
2025
Systemic immunosuppression from ultraviolet radiation exposure inhibits cancer immunotherapy
Durao, P., Budden, T., Mallela, K., Gutteridge, M., Mataloni, I., Gurung, S., . . . Viros, A. (2025). Systemic immunosuppression from ultraviolet radiation exposure inhibits cancer immunotherapy. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 13(10). doi:10.1136/jitc-2025-012527
Stromal lipid species dictate melanoma metastasis and tropism
Gurung, S., Budden, T., Mallela, K., Jenkins, B., von Kriegsheim, A., Manrique, E., . . . Viros, A. (2025). Stromal lipid species dictate melanoma metastasis and tropism. CANCER CELL, 43(6). doi:10.1016/j.ccell.2025.04.001
2024
The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<SUP>G12D</SUP>-driven non-small cell lung cancer
McDaid, W. J., Wilson, L., Adderley, H., Martinez-Lopez, A., Baker, M. J., Searle, J., . . . Malliri, A. (2024). The PI3K-AKT-mTOR axis persists as a therapeutic dependency in KRAS<SUP>G12D</SUP>-driven non-small cell lung cancer. MOLECULAR CANCER, 23(1). doi:10.1186/s12943-024-02157-x
Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma
Saner, F. A. M., Takahashi, K., Budden, T., Pandey, A., Ariyaratne, D., Zwimpfer, T. A., . . . Garsed, D. W. (2024). Concurrent RB1 Loss and <i>BRCA</i> Deficiency Predicts Enhanced Immunologic Response and Long-term Survival in Tubo-ovarian High-grade Serous Carcinoma. CLINICAL CANCER RESEARCH, 30(16), 3481-3498. doi:10.1158/1078-0432.CCR-23-3552
2022
Molecular characterization of fast-growing melanomas
Gaudy-Marqueste, C., Macagno, N., Loundou, A., Pellegrino, E., Ouafik, L., Budden, T., . . . Viros, A. (2022). Molecular characterization of fast-growing melanomas. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 86(2), 312-321. doi:10.1016/j.jaad.2021.07.011
2021
Female Immunity Protects from Cutaneous Squamous Cell Carcinoma
Budden, T., Gaudy-Marqueste, C., Craig, S., Hu, Y., Earnshaw, C. H., Gurung, S., . . . Viros, A. (2021). Female Immunity Protects from Cutaneous Squamous Cell Carcinoma. CLINICAL CANCER RESEARCH, 27(11), 3215-3223. doi:10.1158/1078-0432.CCR-20-4261
Ultraviolet light-induced collagen degradation inhibits melanoma invasion
Budden, T., Gaudy-Marqueste, C., Porter, A., Kay, E., Gurung, S., Earnshaw, C. H., . . . Viros, A. (2021). Ultraviolet light-induced collagen degradation inhibits melanoma invasion. NATURE COMMUNICATIONS, 12(1). doi:10.1038/s41467-021-22953-z
Molecular subtype, biological sex and age shape melanoma tumour evolution
Lotz, M., Budden, T., Furney, S. J., & Viros, A. (2021). Molecular subtype, biological sex and age shape melanoma tumour evolution. BRITISH JOURNAL OF DERMATOLOGY, 184(2), 328-337. doi:10.1111/bjd.19128
2020
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE)
Talhouk, A., George, J., Wang, C., Budden, T., Tan, T. Z., Chiu, D. S., . . . Anglesio, M. S. (2020). Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). CLINICAL CANCER RESEARCH, 26(20), 5411-5423. doi:10.1158/1078-0432.CCR-20-0103
Prognostic gene expression signature for high-grade serous ovarian cancer
Millstein, J., Budden, T., Goode, E. L., Anglesio, M. S., Talhouk, A., Intermaggio, M. P., . . . Ramus, S. J. (2020). Prognostic gene expression signature for high-grade serous ovarian cancer. ANNALS OF ONCOLOGY, 31(9), 1240-1250. doi:10.1016/j.annonc.2020.05.019
2019
<i>MC1R</i> CpG island regulates <i>MC1R</i> expression and is methylated in a subset of melanoma tumours
Budden, T., & Bowden, N. A. (2019). <i>MC1R</i> CpG island regulates <i>MC1R</i> expression and is methylated in a subset of melanoma tumours. PIGMENT CELL & MELANOMA RESEARCH, 32(2), 320-325. doi:10.1111/pcmr.12739
2018
Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials
Meagher, N. S., Schuster, K., Voss, A., Budden, T., Pang, C. N. I., deFazio, A., . . . Friedlander, M. L. (2018). Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials. GYNECOLOGIC ONCOLOGY, 150(3), 527-533. doi:10.1016/j.ygyno.2018.07.013
Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma
Budden, T., van der Westhuizen, A., & Bowden, N. A. (2018). Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma. BMC CANCER, 18. doi:10.1186/s12885-018-4010-9
2016
Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair
Budden, T., Davey, R. J., Vilain, R. E., Ashton, K. A., Braye, S. G., Beveridge, N. J., & Bowden, N. A. (2016). Repair of UVB-induced DNA damage is reduced in melanoma due to low XPC and global genome repair. ONCOTARGET, 7(38), 60940-60953. doi:10.18632/oncotarget.10902
2013
The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis
Budden, T., & Bowden, N. A. (2013). The Role of Altered Nucleotide Excision Repair and UVB-Induced DNA Damage in Melanomagenesis. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 14(1), 1132-1151. doi:10.3390/ijms14011132
Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma
Bowden, N. A., Ashton, K. A., Vilain, R. E., Avery-Kiejda, K. A., Davey, R. J., Murray, H. C., . . . Scott, R. J. (2013). Regulators of Global Genome Repair Do Not Respond to DNA Damaging Therapy but Correlate with Survival in Melanoma. PLOS ONE, 8(8). doi:10.1371/journal.pone.0070424